KPV Peptide: Compounded Access, Uses and the Evidence
Researchers have explored the tiny three-amino-acid peptide KPV for wound healing and inflammatory bowel disease, but human studies are still missing. A new FDA enforcement discretion policy may soon allow prescription access through 503A compounding pharmacies.
KPV peptide is a short fragment of the hormone α-melanocyte-stimulating hormone (α-MSH) that shows anti-inflammatory and tissue-repair activity in cells and animal models, but there are no published human safety trials. On October 28 2026 the U.S. Department of Health and Human Services (HHS) and FDA issued an interim enforcement discretion policy that, for the first time, lets state-licensed 503A pharmacies compound KPV for individual patients if strict quality and reporting conditions are met. Compounded KPV is not FDA-approved, and states may choose not to follow the policy, yet it could soon be prescribed through telehealth services such as Rx.com’s planned KPV offering (coming soon).
- KPV stands for lysine-proline-valine, the last three amino acids of α-MSH that retain anti-inflammatory signaling via NF-κB suppression (Ichiyama et al., 2000).
- In cell studies, KPV restored skin-cell viability and cut IL-1β levels after particulate-matter exposure (Sung et al., 2025).
- Mouse models of colitis show KPV-tagged nanoparticles localize to inflamed colon tissue for up to 36 hours and improve disease scores (Wu et al., 2019) (Laroui et al., 2010).
- FDA staff reviewers found no human safety studies for KPV, yet HHS and FDA issued an interim enforcement discretion policy covering it on Oct 28 2026.
- Compounded KPV prescriptions must come from a U.S.-licensed provider and a 503A pharmacy; “research-use-only” vials sold online remain outside the policy and unregulated.
KPV peptide is a tiny α-MSH fragment with anti-inflammatory potential
KPV is a three-amino-acid sequence (lysine-proline-valine) clipped from positions 11-13 of the hormone α-MSH, and it preserves much of the parent hormone’s ability to calm immune responses. Laboratory work dating back more than two decades shows α-MSH and KPV block the transcription factor NF-κB, lowering production of pro-inflammatory cytokines such as TNF-α and IL-1β (Ichiyama et al., 2000). Because KPV is only 429 Da, it is easier to synthesize and modify than the full 13-amino-acid hormone fragment.
Definition (60 words): KPV peptide is the lysine-proline-valine tripeptide derived from α-melanocyte-stimulating hormone. It has shown anti-inflammatory, antioxidant and antimicrobial activity in cell and animal studies by inhibiting NF-κB signaling and reducing reactive oxygen species. KPV is not approved by the FDA for any indication, and no published human trials have assessed its safety or effectiveness.
KPV may calm inflammation by blocking NF-κB and oxidative stress
Lab studies suggest KPV lowers oxidative stress, then prevents the NF-κB pathway from triggering inflammatory gene expression. In human keratinocytes exposed to fine-particle pollution, KPV cut reactive oxygen species (ROS) and reduced cleaved caspase-3, an apoptosis marker (Sung et al., 2025). In liver cells overloaded with fat, KPV down-regulated AKT-mTOR signaling, limiting fatty-acid synthase expression and lipid accumulation (Lee et al., 2026).
Targeted delivery through PepT1 transporters: The intestinal peptide transporter PepT1 is over-expressed in inflamed colon tissue. Attaching KPV to nanoparticles or fluorescent probes directs cargo to PepT1-rich cells, a strategy that improved drug localization in mouse colitis models (Wu et al., 2019) (Zeng et al., 2017).
Preclinical research shows promise, but no human trials yet
All efficacy data for KPV come from cell cultures or animal studies, which means results may not translate to people. Key findings are summarized below.
| Model | KPV dose / vehicle | Main outcome | Source |
|---|---|---|---|
| DSS colitis mice | KPV-tagged CyA nanoparticles | Weight loss reversed, colon length normalized to 7.8 cm vs 6.1 cm in controls | (Wu et al., 2019) |
| DSS colitis mice | KPV-loaded polysaccharide hydrogel | Histology score fell to 1.2 vs 3.4 in DSS only | (Laroui et al., 2010) |
| Colitis mice, oral SIPPC | proKPV micelles | 3.8× higher colonic KPV levels, improved disease activity index | (Cheng et al., 2026) |
Antimicrobial activity: Earlier work found KPV reduced Staphylococcus aureus colony formation and Candida albicans viability at picomolar to micromolar ranges (Cutuli et al., 2000). These experiments suggest broad innate-immune roles but have not progressed to clinical testing.
The October 2026 FDA enforcement discretion creates a narrow pathway for compounding KPV
The new policy: On Oct 28 2026 HHS and FDA published the “Interim Access Policy for Compounding Using Certain Peptides.” The agency said it “does not intend to take enforcement action” against state-licensed 503A pharmacies and physicians that compound KPV (and five other peptides) for individual patients, provided they follow quality, labeling and adverse-event reporting conditions (federalregister.gov).
What the policy is not: It is not FDA approval, does not add KPV to the 503A bulks list, and does not mandate state adoption. Each state board of pharmacy can decide whether to allow or restrict compounded KPV dispensing. The policy sets no end date and may be withdrawn if safety problems emerge.
| Access pathway | Legal status | Quality controls | Patient safeguards |
|---|---|---|---|
| Prescription compounded KPV | Allowed under 2026 enforcement discretion (not FDA-approved) | Policy conditions on ingredient quality, manufacturing standards, labeling and safety reporting | Provider evaluates need, sets dose, monitors patient |
| Research-use-only (RUO) vials | Unapproved, outside FDA policy | No required testing, often mislabeled or contaminated (Coutinho et al., 2026) | No medical oversight; safety unknown |
How to access KPV safely when compounded products become available
Prescription first: Under the policy, a licensed U.S. clinician must decide KPV is appropriate and write a patient-specific prescription for a state-licensed 503A pharmacy to fill. Rx.com plans to offer prescription compounded KPV through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
Avoid research-only sellers: “Not for human use” or “research only” vials marketed online remain illegal to sell for self-administration and fall outside all quality requirements. Independent testing has found peptide vials frequently under-dosed or contaminated (Coutinho et al., 2026).
State variability: Because states are not bound by the federal policy, some boards of pharmacy may not follow it. Your provider or your state board of pharmacy can tell you what applies where you live.
Should I talk to a provider about compounded KPV?
Check the column that fits your situation:
✅ Might be reasonable to explore
- You have an inflammatory condition such as ulcerative colitis or chronic skin irritation that has not fully responded to standard therapy
- You want to enroll in a monitored trial or prescribed compounded treatment, not self-experiment
- You understand KPV is not FDA-approved and evidence in humans is unknown
- You can attend follow-up visits and report any side effects promptly
🏥 Better to avoid or delay
- You intend to buy RUO vials or use high, bodybuilding-style doses without medical supervision
- You are pregnant, breastfeeding, or planning pregnancy (safety data absent)
- You have a history of severe allergic reactions to injectable medications
- You cannot verify the pharmacy is a licensed 503A facility
- You are seeking KPV to treat cancer or unproven longevity claims
How to recognize possible side effects and when to call your provider
Compounded KPV has no published human safety profile, so providers will watch carefully for unexpected reactions. Contact a healthcare professional right away if you notice:
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Sudden rash, itching or swelling, which could signal an allergic reaction
- Shortness of breath or chest tightness soon after a dose
- Dizziness or fainting that does not resolve quickly
- Severe abdominal pain, bloody stools or persistent diarrhea if using KPV for gut conditions
- Unexplained jaundice (yellowing skin or eyes), a warning sign of liver stress
- Injection site redness that spreads or oozes, suggesting infection
- Mood changes or depression that worsen (call or text 988 if you feel unsafe)
- Any new symptom that you cannot easily explain
Frequently Asked Questions
Scientific References
- Ichiyama T, Sato S, Okada K, et al. The neuroimmunomodulatory peptide alpha-MSH. Ann N Y Acad Sci. 2000.
- Sung J, Ju SY, Park S, et al. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. 2025.
- Wu Y, Sun M, Wang D, et al. A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomater Sci. 2019.
- Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010.
- Lee JY, Lee J, Jung WK, et al. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. 2026.
- Zeng M, Shao A, Li H, et al. Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis. ACS Appl Mater Interfaces. 2017.
- Cheng J, Wu P, Li C, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026.
- Cutuli M, Cristiani S, Lipton JM, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000.
- Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026.
- Federal Register :: Home, Wednesday, October 28th. federalregister.gov.
- fda.gov/media/193346/download
Is KPV peptide the same as BPC-157 or TB-500?
No. KPV is a fragment of α-MSH, while BPC-157 comes from gastric protein and TB-500 is a fragment of thymosin β4. They act on different receptors and signaling pathways, although all three are covered by the 2026 enforcement discretion for 503A compounding.
What forms will compounded KPV come in?
The FDA policy does not specify dosage forms, and Rx.com has not announced which it will offer. A prescriber decides what is appropriate.
Are there any published human doses for KPV?
No. All published work involves cells or animals, so there is no medically accepted dose range for people. Your prescriber will decide an appropriate starting regimen if they believe the potential benefit outweighs unknown risks.
Could KPV help with acne or skin aging?
Cell studies show antioxidant effects in keratinocytes, but no clinical trials have tested KPV for acne, wrinkles or photo-aging. Prescription retinoids such as tretinoin remain the evidence-based first line for those concerns.
How is KPV stored and how long does it last?
Stability data depend on formulation. Your pharmacy will provide storage instructions, often refrigeration for peptide injections. Do not use beyond the beyond-use date on the label.
Where can I follow regulatory updates about compounded peptides?
See our live tracker covering FDA advisory meetings and state actions: FDA 503A peptide review tracker.
